Beyond the Glucose Number
Navigating the CGM Landscape for Sentrix
Role
UX Researcher (Team of 3)
Skills
Market Research, Competitive Analysis, SWOT, Product Positioning, User Story Development
Timeline
4 Weeks, Research — Strategy Recommendation
Scope
Simulated client engagement (bootcamp project)
Overview
Sentrix is Japan's #1 CGM brand with over 1.6 million software users and $525M in revenue, preparing to enter the U.S. market dominated by Abbott (56.74%), Dexcom (35.2%), and Medtronic (6.88%) — a combined 98.8% market share. We conducted a full competitive analysis, identified a white-space positioning as "The Lifestyle Analyst," developed user stories, and built a 5-year P&L projection targeting 2% market share with $520M projected revenue.
Breaking Into a Monopoly
Three incumbents hold 98.8% of the U.S. CGM market. We analyzed each across hardware specs, pricing, insurance coverage, app functionality, and user reviews.
7M users
Abbott Freestyle Libre
"The AI Assistant" — minimalist interface, Libre Assist AI predicts glucose impact from food photos. $150/mo retail, $0–40 insured.
2.9M users
Dexcom G7
"The Automated Bodyguard" — deep insulin pump integration, real-time alert engine. $450–550/mo retail, $30–70 insured.
~6,000 users
Eversense 365
"The Long-Term Clinical Guardian" — one-year implantable sensor for physician-driven management. $3,500–4,000/yr.
Mapping the Competitive Landscape
We mapped competitors along two dimensions: App Intelligence Level (from manual insight to predictive automation) and Lifestyle Integration of Caregiving (from clinical-only to daily-life embedded). This revealed a clear gap: no competitor occupied the quadrant combining high lifestyle integration with caregiver-centered intelligence at a behavioral insight level. All three incumbents focused on clinical automation (Dexcom), everyday simplicity (Freestyle), or passive monitoring (Eversense). None were designed for the care team to interpret why glucose moves — only what it reads.
Critical Product Question
How does Sentrix differentiate in a market where three companies already do "glucose monitoring" better than anyone?
Positioning: "The Lifestyle Analyst"
7-level trend arrows
Unlike competitors showing raw numbers, Sensara visualizes directional glucose trends to help users and caregivers understand trajectory.
Lifelog-centered interface
Integrates food, exercise, and medication data to turn raw readings into behavioral insight.
Caregiver interpretation tools
Enables clinicians and caregivers to understand context, not just data points.
Event comparison for insulin adjustment
Side-by-side comparison of glucose responses to different activities for evidence-based treatment decisions.
User Stories
Mia (10)
Pediatric Patient
Mia's parents were constantly worried about her rapid glucose drops during school and soccer. With Sensara Aero, caregivers could see trends and alerts in real time. Activity context made drops easier to interpret. The endocrinologist used shared reports to adjust treatment. Result: fewer urgent lows, less caregiver anxiety, and more independence for Mia.
David (52)
Adult Patient
A marketing executive whose frequent business travel made glucose control unpredictable. He couldn't tell if spikes were caused by food, stress, or activity. With Sensara Aero's event-logging and contextual overlays, he identified repeat triggers, shared evidence-based reports with his clinician, and made targeted routine adjustments. Result: higher time-in-range, fewer mystery spikes.
SWOT Analysis
strengths
- • Smallest form factor with 30-minute warm-up
- • Integrated data sharing for remote dosage management
- • FDA approval and data infrastructure secured
weaknesses
- • Zero brand awareness and trust in the U.S.
- • Data privacy concerns regarding provider access
- • No current market share in a heavily consolidated market
opportunities
- • Predictive glucose analytics via AI/ML
- • Free trial strategy to convert existing CGM users
- • Aggressive pricing ($75/month) to undercut incumbents
threats
- • Insurance qualification uncertainty
- • Competitor financial depth and ability to cut prices
- • Potential disruption from non-invasive monitoring (Apple, Samsung)
Outcome
Before
0%
U.S. market share
0
U.S. users
Unknown
Competitive positioning
After
2%
Target U.S. market share
$520M
Projected 5-year revenue
"Lifestyle Analyst"
Clear differentiated positioning
Reflection
The biggest insight from this project was that competitive analysis in a monopolized market isn't about finding a better feature — it's about finding a dimension of competition that incumbents aren't even measuring. Abbott, Dexcom, and Eversense are all excellent at what they do. The opportunity wasn't to out-automate Dexcom or out-simplify Abbott. It was to redefine what a CGM companion app should do: shift from passive monitoring to active behavioral analysis, and from patient-only tools to caregiver-inclusive platforms. This reframing — changing the axes of competition rather than trying to win on existing ones — is a principle I've carried into product thinking more broadly.
Thanks for reading!